CJC-1295 (no DAC)¶

Identification¶

Property	Value
CAS Number	863288-34-0
Molecular Formula	C₁₅₂H₂₅₂N₄₄O₄₂
Molecular Weight	~3,367.1 Da
Sequence	Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys-NH₂
Amino Acid Count	30 (no DAC linker)
Appearance	White to off-white lyophilized powder
Purity Standard	≥99% by HPLC
Solubility	Soluble in sterile or bacteriostatic water
Storage	2–8°C, desiccated, protect from light

Category: Muscle Growth

Catalog SKU: PSH-CJC1295-2MG

Research Background¶

CJC-1295 without DAC (also known as Mod GRF 1-29) is the same 30-amino acid GHRH analogue as the DAC variant, but without the C-terminal maleimidopropionyl linker. This single structural difference produces a fundamentally different pharmacokinetic profile: instead of 8-day sustained GH elevation, the no-DAC variant has a short ~30-minute half-life producing a discrete GH pulse that closely mimics endogenous pulsatile secretion patterns.

Key Mechanisms¶

Mechanism	Details
GHRH-R Agonism	Full receptor activation → cAMP → GH synthesis and release from somatotrophs
Short Half-Life	~30 minute plasma half-life → discrete GH pulse → mimics endogenous GHRH
No Albumin Binding	Absence of DAC linker → no serum albumin conjugation → renal clearance at normal rate

Research Focus Areas¶

Pulsatile GH¶

Physiological GH pulse pattern — short-duration GHRH-R activation

Post-Exercise GH¶

Pulse timing relative to exercise-induced GH window

Combination Protocols¶

Paired with GHS-R agonist (Ipamorelin/GHRP-2) for synergistic pulse

GH Axis Research¶

Endogenous pulsatile secretion pattern studies

Available Configurations¶

Configuration	Content	Best For
Standard Kit	2 mg × 10 vials	Pulsatile GH research; evaluation
Bulk Kit	5 mg × 10 vials	Chronic pulse protocols; repeat orders
Custom	Custom mg × custom vials	OEM; private-label

Tiered Wholesale Pricing¶

Volume	Discount	For
1 kit	List price	Evaluation; competitive analysis
5+ kits	10% off	Initial portfolio expansion
20+ kits	20% off	Mid-size distributors
50+ kits	30% off	Regional distributors

Quality Specifications¶

Parameter	Method	Criterion
Purity	HPLC at 214 nm, C18 column	≥99.0% peak area
Identity (MW)	ESI-MS	~3,367.1 ± 1.0 Da
Appearance	Visual inspection	White to off-white powder
Peptide Content	Amino acid analysis	≥80% net peptide
No DAC Confirmation	HPLC-MS	Absence of maleimidopropionyl mass adduct

Frequently Asked Questions¶

Q1: Why choose CJC-1295 without DAC?¶

Choice depends on research objective. No DAC = ~30 min half-life = discrete physiological GH pulse. With DAC = ~8 day half-life = sustained GH/IGF-1 elevation. Use no DAC for pulsatile GH studies; use DAC for chronic activation.

Q2: Is CJC-1295 (no DAC) the same as Mod GRF 1-29?¶

Essentially yes. Both refer to the same 30-amino acid GHRH analogue with four substitutions but without the DAC linker. Both terms describe the short-acting, non-albumin-binding variant.

Q3: What is the optimal partner peptide?¶

Ipamorelin is preferred for pulsatile protocols: CJC-1295 provides GHRH signal, Ipamorelin suppresses somatostatin tone → synergistic, clean GH pulse. GHRP-2 can be used when maximum pulse amplitude is preferred over selectivity.

Q4: What is the half-life difference vs DAC variant?¶

No DAC: ~30 minutes → discrete GH pulse. With DAC: ~8 days (via albumin conjugation). This ~400-fold difference is entirely due to the maleimidopropionyl DAC linker.

Q5: How is absence of DAC verified?¶

HPLC-MS confirms the molecular ion without the maleimidopropionyl mass adduct (+97 Da absent vs DAC variant). Included in every batch-specific COA.

Key Research References¶

Reference	PMID	Key Finding
Teichman SL et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." J Clin Endocrinol Metab. 2006;91(3):799–805.	16352683	CJC-1295 (both DAC/no DAC forms) engineering with four amino acid substitutions for enhanced GHRH receptor activity and proteolytic stability
Ionescu M & Frohman LA. "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog." J Clin Endocrinol Metab. 2006;91(12):4792–4797.	17018654	The no-DAC variant mimics endogenous pulsatile GH secretion; DAC variant provides sustained GHRH-R activation

Stability & Storage¶

Condition	Degradation Profile
Lyophilized Storage	24 months at 2–8°C in desiccated environment, protect from light
Short Half-Life (no DAC)	~30 minute plasma half-life by design; no albumin binding means rapid renal clearance. This is the intended pharmacological property — not degradation
Neutral pH (6.0–7.5)	Stable; recommended for reconstitution in sterile or bacteriostatic water
Reconstituted Solution	24 h at 2–8°C; aliquot and freeze at −20°C for extended use. Avoid repeated freeze-thaw
No DAC Verification	Absence of maleimidopropionyl mass adduct (+97 Da) confirmed by HPLC-MS in every batch

Source & Purchase¶

For research-grade CJC 1295 NO DAC and related compounds in this category, visit the PeptideSourceHub category page for bulk pricing and available specifications.

Browse CJC 1295 NO DAC & Related Products →

Product	Link
CJC-1295 (DAC)	cjc-1295-dac.md — Long-acting GHRH analogue with ~8-day half-life
Ipamorelin	ipamorelin.md — Selective GHS-R1a agonist for clean GH pulse
GHRP-2	ghrp-2.md — Potent ghrelin receptor agonist
HGH (Somatropin)	hgh.md — 191-aa human growth hormone